Zensar Technologies Allots 1,200 Equity Shares Under ESOP Exercise; Share Capital Rises to Rs. 454,991,308

Zensar Technologies Limited's Nomination and Remuneration Committee approved the allotment of 1,200 fully paid equity shares on May 07, 2026, following the exercise of Employee Stock Options (ESOPs) previously granted to eligible employees. The allotment was formally intimated to the stock exchanges in accordance with applicable regulatory requirements.

ESOP Allotment Details

The committee approved the issuance of equity shares at a face value of Rs. 2/- each against ESOP exercises. The key parameters of this allotment are summarised below:

Parameter: Details Allotment Date: May 07, 2026 Number of Shares Allotted: 1,200 Face Value per Share: Rs. 2/- Nature of Shares: Fully paid equity shares Approving Authority: Nomination and Remuneration Committee

Impact on Share Capital

Consequent to this allotment, Zensar Technologies' issued and subscribed share capital has been revised upward. The updated capital structure as on May 07, 2026, is as follows:

Capital Structure Parameter: Post-Allotment Issued & Subscribed Share Capital: Rs. 454,991,308 Total Number of Equity Shares: 227,495,654 Face Value per Share: Rs. 2/-

The allotment was signed off by Anand Daga, Company Secretary of Zensar Technologies Limited, and the intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited for their records.

Zensar Technologies Limited has notified the stock exchanges of the availability of the transcript from its earnings call held in connection with the financial results for the quarter and year ended March 31, 2026. The disclosure was made via a regulatory filing dated May 4, 2026, in continuation of the company's earlier communication dated April 17, 2026.

Earnings Call Details

The earnings call was conducted on Friday, April 24, 2026, at 5:00 p.m. (IST). The discussion covered the financial results of the company for the quarter and year ended March 31, 2026. Key details of the filing are summarised below:

Parameter: Details Earnings Call Date: Friday, April 24, 2026 Call Time: 5:00 p.m. (IST) Results Period: Quarter and year ended March 31, 2026 Filing Date: May 4, 2026 Transcript Availability: Company investor relations website

Transcript Availability

The transcript of the earnings call has been made available on the company's official investor relations portal at https://www.zensar.com/investors/investor-corner . The filing was submitted to both BSE Limited and the National Stock Exchange of India Limited for information and dissemination purposes.

The regulatory communication was signed by Anand Daga, Company Secretary of Zensar Technologies Limited, on May 4, 2026.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.